Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


29. March 2021 | 08:15 CET

Cardiol Therapeutics, Bayer, Formycon: These pharma stocks could explode!

  • Biotechnology
Photo credits: proactiveinvestors.com

According to official statistics, diseases of the cardiovascular system, such as heart failure, coronary heart disease or myocardial infarction, are the No.1 cause of death in Germany. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. Thus, on a global average, a good 30% of all deaths are attributable to cardiovascular disease. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. But there are many other dangers to our health. Reason enough to take a closer look.

time to read: 3 minutes by André Will-Laudien
ISIN: CA14161Y2006 , DE000BAY0017 , DE000A1EWVY8


 

Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author


Cardiol Therapeutics - Focus on heart disease

The causes of cardiovascular diseases are manifold and can be divided into influenceable and non-influenceable risk factors. Non-influenceable risk factors include age, gender and genetic predisposition. Influenceable risk factors include high blood pressure, diet, diabetes, obesity, smoking, lack of exercise, and excessive alcohol consumption, the scourges of modern society.

A distressing combination occurs when simple flu-like infections combined with stress-related factors result in severe heart muscle inflammation. Canadian biotechnology Company Cardiol Therapeutics has focused on the research and development of anti-inflammatory therapies to treat cardiovascular disease. The Company's lead product is CardiolRx™, a proprietary pharmaceutically produced high-concentration, ultra-pure oral cannabidiol (“CBD”) formulation.

Of interest now are the ongoing tests with COVID-19 patients who are available for a clinical trial. Especially in the area of currently emerging mutations, the combination of cardiac symptoms and acute pulmonary dysfunction can carry a significant risk of death. A Phase 1 trial has already been completed with CardiolRx™. The hope now is that this CBD formulation can be a cardioprotective therapy to reduce mortality and major cardiovascular events in COVID-19 patients who have a prior history of, or risk factors for, cardiovascular disease.

Cardiol Therapeutics has addressed attractive areas with its current research pipeline, which could multiply the current market capitalization of EUR 100 million if the related success stories are reported. Therefore, take the stock, which is also traded in Germany, into your shortlist.

Bayer - The search for final settlements

In 2020, chemical Company Bayer posted the highest loss in its corporate history due to its acquisition of US seed and pesticide producer Monsanto. The Leverkusen-based Company last reported a net loss of EUR 10.5 billion, mainly due to "special charges" of EUR 23 billion. These relate to provisions for lawsuits concerning the Monsanto pesticides, glyphosate and dicamba, the industrial chemical PCB which the US company also produces, and the sterilization spiral Essure.

Some 125,000 plaintiffs blame Monsanto's weedkiller Roundup, which contains the active ingredient glyphosate, for their cancer and are seeking damages. Farmers in the US also blame Monsanto because dicamba has drifted off their neighbors' fields and damaged crops. In the US, some 40,000 women are also suing Bayer, claiming that Essure caused them to suffer injuries to their uterus and fallopian tubes, among other things.

After years of litigation, the chemical Company has accepted the first US court ruling that the world's best-selling pesticide glyphosate caused cancer. This ruling makes the guilty verdict against the Company legally binding, and Bayer says it has already paid Johnson his USD 20.5 million in damages. German farmers also regularly use glyphosate in their fields. The EU is currently considering whether to extend or allow the approval of the controversial agent to expire.

For Bayer shares, the decision will soon be made because, after a low of around EUR 40, resistance at EUR 56 is now on the horizon. Prices above this would open up the potential to EUR 80.

Formycon - Also well equipped for COVID-19

Some time ago, the biosimilar manufacturer Formycon attracted attention with an application against COVID-19. There is news on the active ingredient FYB207, which has recently been in the spotlight mainly due to tests for use against coronaviruses. The in vitro neutralization of SARS-CoV-2 variants by FYB207 show that the active ingredient has an even stronger effect against the B.1.1.7 mutant of the virus, which is considered particularly infectious, than against earlier variants. This is excellent news in the fight against the pandemic.

SARS-CoV-2 and other coronaviruses use the protein ACE2 on human cells' surface as an entry portal for respiratory infections. Formycon has therefore fused the human ACE2 protein to the constant portion of human immunoglobulin G4 (IgG4) using computational structural design, creating a very effective SARS-CoV-2 blocker that completely prevents cell infection in vitro.

However, FYB207 is still far from potential approval as a drug. According to the Company, preclinical activities and preparations for entering clinical trials with FYB207 are fully on track. Still, experience has shown that the trials are lengthy and costly in their design. In our opinion, a clinical phase may already occur in the second half of 2021. The share has consolidated up to EUR 58 and is now gaining new momentum.


Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

14. October 2021 | 11:27 CET | by André Will-Laudien

BioNTech, Cardiol Therapeutics, CureVac: A decade's worth of ideas!

  • Biotechnology

Biotechnology remains a hotly contested industry. In the fight against a wide range of diseases, biopharmaceuticals are the first port of call. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. By directly applying findings from biology and biochemistry, technically functional elements are identified. The central objectives are to research, improve and develop processes for the production of relevant substances. Often research goes nowhere; we take a look at the sector.

Read

12. October 2021 | 12:32 CET | by Carsten Mainitz

Defence Therapeutics, BioNTech, Valneva - When will things pick up again?

  • Biotechnology

Biotechnology companies can experience a significant, sometimes even exponential, increase in value virtually overnight with a new, successful active ingredient. BioNTech is a prime example of this. But not every research effort leads to success, and CureVac shareholders can tell you a thing or two about that. Canada's Defence Therapeutics and Valneva have innovative research pipelines. Where should investors consider investing now?

Read

08. October 2021 | 10:25 CET | by André Will-Laudien

BioNTech, Defence Therapeutics, Valneva, Formycon - Close to the bio-revolution!

  • Biotechnology

Portugal is one of the countries with the highest vaccination rate, with 86% of the population already vaccinated. Approximately 98% of those eligible for vaccination - including everyone over the age of 12 - have been vaccinated. Germany, with about 64%, is one of the more vaccine-weary nations. What is the secret of the Portuguese? The government relied on an opinion maker from within its ranks, Admiral Gouveia e Melo. An expert in complicated logistical tasks in the military, he was appointed in February as the top leader of the national vaccination campaign. He is never seen without his military combat uniform in numerous public television appearances - and when asked how other countries can move their own vaccination effort forward, the admiral did not hesitate to offer his best advice: "You have to find people who are not politicians." Where are the current opportunities in the vaccination sector?

Read